Tempus AI Inc (TEM) Actualités

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced...

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced...

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced...

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported...

Tempus to Report Third Quarter 2024 Financial Results on November 4

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for...

Tempus to Report Third Quarter 2024 Financial Results on November 7

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for...

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an...

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced...